Citations

Showing 10 of 108162 citations.

Hemodynamic Basis for Dyspnea in Pulmonary Vein Stenosis
Jain, C. Charles , Holmes, David R. , Egbe, Alexander C. , Miranda, William R.

Mayo Clinic

Circulation: Heart Failure | March 25, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circheartfailure.120.007820 | PMID 33761753 Get It

A Case of Anaplasmosis during a Warm Minnesota Fall
Khera, Kushal D. , Southerland, Danielle M., Miller, Nathaniel E. , Garrison, Gregory M. , Miller, Nathaniel E

Mayo Clinic

Journal of Primary Care & Community Health | March 25, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211005895 | PMID 33764206 Get It

A healthy 33 year old male presented in December with a 3 week history of fever and fatigue. He had been deer-hunting in northern Minnesota 1 month prior and had sustained a tick bite. Extensive laboratory investigations and a lumbar puncture were conducted. He was empirically with doxycycline and had rapid improvement in his symptoms. Subsequently, PCR and serologic testing returned positive for Anaplasma phagocytophlium. Anaplasmosis is a tick-borne illness caused by the bacterium Anaplasma phagocytophilum and is typically seen in the warmer months. This patient’s presentation in December was uncommon for a tick-borne illness in Minnesota. Regional weather records demonstrated unseasonably warm temperatures during the patient’s trip. Ixodes ticks are known to be sensitive to temperature and humidity, which likely contributed to increased tick activity, leading to disease transmission. This case highlights the importance for clinicians to be aware of local weather patterns and how this might influence seasonal disease presentations.
Patient on Immunomodulatory Therapy Experiencing Joint Pain and Skin Lesions: A Case Report
Greenwood, Jason D. , Nielsen, Nathaniel T., Miller, Nathaniel E. , Nielsen, Nathaniel, Miller, Nathaniel E

Mayo Clinic

Journal of Primary Care & Community Health | March 25, 2021 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/21501327211005894 | PMID 33764183 Get It

A woman in her late fifties was admitted to the Family Medicine Inpatient Service directly from Rheumatology clinic for polyarticular pain and erythema with concern for infection. She was taking immunosuppressant medications for a history of multiple autoimmune diseases. Examination showed increasing erythema and tenderness on the upper and lower extremity joints. Histologic evaluation, surgical evaluation, and cultures were consistent with mycobacterium haemophilum infection. Mycobacterium haemophilum is an uncommon opportunistic infection that usually affects immunocompromised patients. The patient was treated with a multi-drug antibiotic regimen for several months due to drug resistance. Although this opportunistic infection is not common it should be considered in the differential of immunocompromised patients with skin and articular symptoms. Treatment outcomes are usually favorable if it caught earlier in the course.
Defining Spatial Relationships Between Spinal Cord Axons and Blood Vessels in Hydrogel Scaffolds
Oswald, David, Papamichalopoulos, Sophia , Kelly, Domhnall , Summer, Priska , Polzin, Michael J., Hakim, Jeffrey S. , Schmeichel, Ann M., Chen, Bingkun , Yaszemski, Michael J. , Windebank, Anthony J. , Madigan, Nicolas N. , Siddiqui, Ahad M. , Polzin, Michael, Hakim, Jeffrey, Polzin, Michael

Mayo Clinic

Tissue Engineering Part A | March 25, 2021 | Volume: 27 | Issue: 11-12 | Pages: 648-664

10.1089/ten.tea.2020.0316 | PMID 33764164 Get It

Association of prurigo nodularis and infectious disease hospitalizations: a national cross‐sectional study
Sutaria, Nishadh , Choi, Justin , Adawi, Waleed , Pollock, Jordan R. , Biles, Natalia Fontecilla, Gabriel, Sylvie , Kwatra, S G , Pollock, Jordan Riley , Roh, Youkyung Sophie , Alphonse, Martin Prince , Lai, J., Chavda, Rajeev

Mayo Clinic

Clinical and Experimental Dermatology | March 25, 2021 | Volume: 46 | Issue: 7 | Pages: 1236-1242

10.1111/ced.14652 | PMID 33763852 Get It

Machine learning‐based decision tree classifier for the diagnosis of progressive supranuclear palsy and corticobasal degeneration
Koga, Shunsuke , Zhou, Xiaolai , Dickson, Dennis W. , Koga, Shunsuke , Dickson, Dennis W

Mayo Clinic

Neuropathology and Applied Neurobiology | March 25, 2021 | Volume: 47 | Issue: 7 | Pages: 931-941

10.1111/nan.12710 | PMID 33763863 Get It

AbstractAimsThis study aimed to clarify the different topographical distribution of tau pathology between progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and establish a machine learning‐based decision tree classifier.MethodsParaffin‐embedded sections of the temporal cortex, motor cortex, caudate nucleus, globus pallidus, subthalamic nucleus, substantia nigra, red nucleus, and midbrain tectum from 1020 PSP and 199 CBD cases were assessed by phospho‐tau immunohistochemistry. The severity of tau lesions (i.e., neurofibrillary tangle, coiled body, tufted astrocyte or astrocytic plaque, and tau threads) was semi‐quantitatively scored in each region. Hierarchical cluster analysis was performed using tau pathology scores. A decision tree classifier was made with tau pathology scores using 914 cases. Cross‐validation was done using 305 cases. An additional ten cases were used for a validation study.ResultsCluster analysis displayed two distinct clusters; the first cluster included only CBD, and the other cluster included all PSP and six CBD cases. We built a decision tree, which used only seven decision nodes. The scores of tau threads in the caudate nucleus were the most decisive factor for predicting CBD. In a cross‐validation, 302 out of 305 cases were correctly diagnosed. In the pilot validation study, three investigators made a correct diagnosis in all cases using the decision tree.ConclusionRegardless of the morphology of astrocytic tau lesions, semi‐quantitative tau pathology scores in select brain regions are sufficient to distinguish PSP and CBD. The decision tree simplifies neuropathologic differential diagnosis of PSP and CBD.
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Venner, Christopher P. , Offner, Fritz , White, Darrell , Karlin, Lionel, Benboubker, Lotfi , Rigaudeau, Sophie , Rodon, Philippe, Voog, Éric , Suzuki, Kenshi , Zhang, Xiaoquan , Twumasi‐Ankrah, Philip, Rifkin, Robert M. , Kumar, Shaji , Richardson, Paul G. , Benboubker, Lotfi , Voog, Eric , Yoon, Sung-Soo , Suzuki, Kenshi , Shibayama, Hirohiko , Yung, Godwin , Kumar, Shaji K , Rajkumar, S Vincent , Facon, Thierry T.F. , Bahlis, Nizar Jacques , Karlin, Lionel , Yoon, Sung‐Soo , Shibayama, Hirohiko , Yung, Godwin , Moreau, Philippe , Lonial, Sagar , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent

Mayo Clinic

Blood | March 24, 2021 | Volume: 137 | Issue: 26 | Pages: 3616-3628

10.1182/blood.2020008787 | PMID 33763699 Get It

Abstract Continuous lenalidomide-dexamethasone (Rd)-based regimens are among the standards of care in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. The oral proteasome inhibitor ixazomib is suitable for continuous dosing, with predictable, manageable toxicities. In the double-blind, placebo-controlled TOURMALINE-MM2 trial, transplant-ineligible NDMM patients were randomized to ixazomib 4 mg (n = 351) or placebo (n = 354) plus Rd. After 18 cycles, dexamethasone was discontinued and treatment was continued using reduced-dose ixazomib (3 mg) and lenalidomide (10 mg) until progression/toxicity. The primary endpoint was progression-free survival (PFS). Median PFS was 35.3 vs 21.8 months with ixazomib-Rd vs placebo-Rd, respectively (hazard ratio [HR], 0.830; 95% confidence interval, 0.676-1.018; P = .073; median follow-up, 53.3 and 55.8 months). Complete (26% vs 14%; odds ratio [OR], 2.10; P < .001) and ≥ very good partial response (63% vs 48%; OR, 1.87; P < .001) rates were higher with ixazomib-Rd vs placebo-Rd. In a prespecified high-risk cytogenetics subgroup, median PFS was 23.8 vs 18.0 months (HR, 0.690; P = .019). Overall, treatment-emergent adverse events (TEAEs) were mostly grade 1/2. With ixazomib-Rd vs placebo-Rd, 88% vs 81% of patients experienced grade ≥3 TEAEs, 66% vs 62% serious TEAEs, and 35% vs 27% TEAEs resulting in regimen discontinuation; 8% vs 6% died on study. Addition of ixazomib to Rd was tolerable with no new safety signals and led to a clinically meaningful PFS benefit of 13.5 months. Ixazomib-Rd is a feasible option for certain patients who can benefit from an all-oral triplet combination. This trial was registered at www.clinicaltrials.gov as #NCT01850524.
Back to the Future: The End of the Steroid Century?
Huntoon, Marc A.

Mayo Clinic

Pain Physician | March 24, 2021 | Volume: 6;11 | Issue: 12;6 | Pages: 713-716

10.36076/ppj.2008/11/713 Get It

The dose magnifying glass quality assurance system for daily proton therapy range verification
Debrot, Emily , Mundy, Daniel W. , Guatelli, Susanna , Petasecca, Marco , Perevertaylo, Vladimir L. , Beltran, Chris , Rosenfeld, Anatoly , Debrot, E , Guatelli, S , Rosenfeld, A B , Beltran, Chris J

Mayo Clinic

Physics in Medicine & Biology | March 24, 2021 | Volume: 66 | Issue: 9 | Pages: 094001

10.1088/1361-6560/abf1b9 | PMID 33761472 Get It

Abstract Proton therapy has a distinct dosimetric advantage over conventional photon therapy due to its Bragg peak profile. This allows greater accuracy in dose delivery and dose conformation to the target, however it requires greater precision in setup, delivery and for quality assurance (QA) procedures. The AAPM TG 224 report recommends daily range and spot position checks with tolerance on the order of a millimetre. Daily QA systems must therefore be efficient for daily use and be capable of sub-millimetre precision however few suitable commercial systems are available. In this work, a compact, real-time daily QA system is optimised and characterised for proton range verification using an ad-hoc Geant4 simulation. The system is comprised of a monolithic silicon diode array detector embedded in a perspex phantom. The detector is orientated at an angular offset to the incident proton beam to allow range in perspex to be determined for flat proton fields. The accuracy of the system for proton range in perspex measurements was experimentally evaluated over the full range of clinical proton energies. The mean R 100 , R 90 and R 80 ranges measured with the system were accurate within ±0.6 mm of simulated ranges in a perspex phantom for all energies assessed. This system allows real-time read-out of individual detector channels also making it appropriate for temporal beam delivery diagnostics and for spot position monitoring along one axis. The system presented provides a suitable, economical and efficient alternative for daily QA in proton therapy.
An Assessment of the Association Between Smoking Status, Pain Intensity, and Functional Interference in Patients with Chronic Pain
Weingarten, Toby N.

Mayo Clinic

Pain Physician | March 24, 2021 | Volume: 5;11 | Issue: 10;5 | Pages: 643-653

10.36076/ppj.2008/11/643 Get It

Background: This article examines the association between smoking and pain intensity and functional interference in a heterogeneous group of patients evaluated at a tertiary outpatient pain clinic. Current smoking is associated with less favorable clinical presentations. Objective: This study was conducted to determine if the smoking status of patients seen in an outpatient pain clinic is associated with differences in pain intensity and interference. Methods: Surveys were mailed to 500 consecutive new patients evaluated at an outpatient pain clinic. Measures included the Brief Pain Inventory (BPI) and the Fagerström Test for Nicotine Dependence (FTND). Univariate analyses compared BPI scores between smokers and non-smokers. Mean BPI scores were compared between smoking status via analysis of covariance (adjusted for demographic variables which differed significantly by smoking status). A p value ≤ 0.05 was accepted as significant. Results: Survey completion rate was 46%, and 14.7% were current smokers. Smokers were younger, and more likely to be male and unemployed. Smokers had higher scores on all the pain intensity BPI scales (p < 0.01), and higher scores (indicating greater functional impairment) on the general activity (p = 0.007), mood (p = 0.003), normal work (p = 0.02), relationships (p = 0.04), sleep (p < 0.001), and life enjoyment (p = 0.03) BPI functional impairment scales. Severe nicotine dependence was associated with greater pain now, (p = 0.05), and greater functional interference on mood (p = 0.005), normal work (p = 0.02) and life enjoyment (p = 0.04) BPI scales. Conclusion: In patients who completed evaluation in an outpatient pain clinic, current cigarette smokers reported significantly greater pain intensity and pain interference with functioning. Symptoms were more pronounced in smokers with more severe nicotine dependence. Key words: smoking status; outpatient pain management; brief pain inventory; Fagerström test for nicotine dependence